In bone marrow samples from multiple myeloma and B-cell acute lymphoblastic leukemia (ALL) patients, MRD: A powerful way to assess response and predict patient outcomes. Measurable (or minimal) residual disease (MRD) refers to the small number of cancer cells that may remain in a patient’s body during and after treatment. Clinical practice guidelines recognize that MRD status is a reliable indicator of clinical outcome and response to therapy in MM and ALL patients.1,2

The clonoSEQ® Assay detects and monitors MRD in bone marrow samples from patients with multiple myeloma or B-ALL. Clinical outcomes are strongly associated with MRD levels as measured by clonoSEQ.3

Clinicians who leverage the latest advances in personalized medicine use clonoSEQ to:3

- Help Predict clinical outcomes
- Assess treatment response
- Monitor remission status
- Detect potential relapse

Why choose clonoSEQ?3

- **Deep sensitivity:** Able to detect one cancerous cell in 1 million normal cells*
- **Reliable results:** First MRD assay to demonstrate accuracy, precision and reproducibility that meets FDA standards
- **Easy to order:** Ordered through a central reference lab with 7-day turnaround
- **Broad patient experience:** >10,000 patients tested to date
- **Widely utilized by experts:** 27 of 28 NCCN institutions currently using in clinical trials and/or clinical practice

How clonoSEQ® works3

**Clonality (ID) Test**

Identifies trackable malignant DNA sequence(s) in a high-disease load sample collected at the time of diagnosis or relapse

**Tracking (MRD) Test**

Quantifies and tracks MRD during or after treatment in a freshly-drawn bone marrow or blood† sample

Remember: A successful ID test is required BEFORE an MRD test can be completed

---

*With sufficient input material; †Blood-based MRD testing is available as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. This use of clonoSEQ has not been approved or cleared by the FDA.

clonoSEQ® is an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in B-cell acute lymphoblastic leukemia and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ® is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. clonoSEQ® is available by prescription only. clonoSEQ® results should always be used in combination with clinical examination, patient medical history, and other findings. For important information about the FDA-cleared uses of clonoSEQ, including test limitations, visit clonoSEQ.com/technical-summary.
clonoSEQ Clonality (ID) and Tracking (MRD) reports

B-CELL CLONALITY (ID) REPORT

METHOD OF ANALYSIS

The clonoSEQ Assay uses multiplex polymerase chain reaction (PCR) and next-generation sequencing (NGS) to identify and quantify rearranged IgH (VDJ), IgH(DJ), IgK, and IgL receptor gene sequences, as well as translocated BCL1/IgH(J) and BCL2/IgH(J) sequences, in DNA extracted from specimens from patients with lymphoid malignancies.

CRITERIA FOR DEFINING “DOMINANT” SEQUENCES

1. The sequence must be carried by at least 40 estimated genome equivalents in the analyzed sample.
2. The sequence must comprise at least 0.2% of the total nucleated cells in the sample.
3. The sequence must comprise at least 3% of all like sequences (IGH-involved, IGK, and IGL are considered independently).
4. The sequence must be discontinuously distributed (≤5 sequences in the next decade of sequences when ranked by frequency).
5. The results obtained from this assay should always be used in combination with the clinical examination, patient medical history, and other findings.

RESULTS SUMMARY

In Vitro Diagnostic Use. Rx Only.

CLONALITY RESULT

2. Sequences Identified

6 residual clonal cells per million nucleated cells (Range: 6 - 27)

Set up account

Access reports online

Order online

Samples processed

Turnaround time is approximately 7 days for fresh specimens and 14 days for stored/archived specimens

Fill out Physician Registration Form

Provide details on your practice and establish contact preferences

I want to order clonoSEQ. How do I get started?

Contact Clinical Services

Contact Adaptive’s Clinical Services team at 1-888-552-8988 or clinicalservices@adaptivebiotech.com

Contact Adaptive’s Clinical Services team at 1-888-552-8988 or clinicalservices@adaptivebiotech.com

Access reports online

Patient reports are available through the Diagnostic Portal or secure fax

Set up account

Obtain an account setup form for your practice